NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
Tesaro, Inc.
AstraZeneca
Presage Biosciences
pharmaand GmbH
Bristol-Myers Squibb
Peregrine Pharmaceuticals
Valerio Therapeutics
Bayer